|
HS Code |
736998 |
| Chemical Formula | C13H22N2O5 |
| Molecular Weight | 286.324 g/mol |
| Iupac Name | (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid |
| Chirality | Has two chiral centers (2S,5S) |
| Physical State Predicted | Solid (due to its relatively polar functional groups promoting intermolecular interactions) |
| Solubility | Likely soluble in polar organic solvents like methanol, ethanol, DMSO; less soluble in non - polar solvents like hexane |
| Boiling Point Estimated | Relatively high boiling point due to hydrogen - bonding and polar interactions, likely above 300°C |
| Melting Point Estimated | Above 150°C considering its molecular structure and intermolecular forces |
| Functional Groups | Contains amide, ester, carboxylic acid, and pyrrolidine ring |
| Acidity | The carboxylic acid group can act as an acid, with an estimated pKa around 3 - 5 for the carboxylic acid moiety |
As an accredited (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 10 grams of (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid in sealed vial. |
| Shipping | (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid is shipped with strict adherence to chemical transport regulations. It's carefully packaged to prevent damage and ensure safe transit, typically via specialized carriers. |
| Storage | (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid should be stored in a cool, dry place, away from heat and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Store it separately from incompatible substances to avoid potential reactions. |
What Pre-Processing Validations Align with ICH Q7 Section 12.7 for Peptide Intermediate Shipment?In the convergent synthesis of voxilaprevir (GS-9857), the fully elaborated C-terminal macrocyclic precursor is assembled via sequential amide couplings, wherein (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid serves as the pre-activated P2–P3 dipeptide acid. This fragment is brought into reaction with the P1–P2 amine hydrochloride in a 1.0:1.03 stoichiometric ratio, mediated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and 1-hydroxybenzotriazole (HOBt) in anhydrous acetonitrile at –5 °C to 0 °C. The downstream macrolactamization step, conducted under pseudodilution conditions (0.005 M) with 2.4 eq. of N,N-diisopropylethylamine, exhibits an epimerization cliff: if the temperature deviates above +8 °C during the 36-hour cyclization, the (2S,5S)/(2R,5S) diastereomeric ratio degrades from ≥99.5:0.5 to 96:4, rendering the batch unrecoverable by seeded crystallization. Regulatory alignment with ICH Q11 requires that the intermediate’s (S,S) configuration be verified via chiral stationary phase HPLC (column: CHIRALPAK IA-3, 250 × 4.6 mm; mobile phase: n-hexane/ethanol/trifluoroacetic acid 80:20:0.1 v/v/v) with retention times for the (2S,5S) enantiomer at 12.7 ± 0.2 min. The final dosage form—voxilaprevir 100 mg film-coated tablet co-formulated with sofosbuvir and velpatasvir—must comply with USP <232>/<233> elemental impurity limits, specifically a cadmium concentration not exceeding 2.0 μg/g. On industrial scale, the intermediate is handled in 316L stainless steel agitated filter-dryers with a nitrogen blanket, and any residual palladium from the catalytic hydrogenolysis step is controlled below 10 ppm.Evaluating Diastereoselectivity Cliffs During (2S,5S)-5-Methylpyrrolidine Fragment Activation for Macrocyclic Protease InhibitorsWhen the methoxycarbonyl-valyl-5-methylproline acid is converted to its pentafluorophenyl ester for alternative coupling strategies, the activation chemistry must be confined to a narrow processing window. The conversion proceeds via treatment with pentafluorophenol / 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in ethyl acetate at –10 °C; exceeding –5 °C triggers a base-catalysed diketopiperazine formation pathway that consumes 4–7 % of the activated species within 45 minutes. Protocols aligned with ICH Q7 Section 8.5 (process validation) mandate real-time FTIR monitoring of the ester carbonyl band at 1812 cm⁻¹ to terminate the activation when the diacid impurity index rises above 0.3 area %. The resultant activated ester is reacted in a subsequent displacement step with a macrocycle P1 amino alcohol at a molar ratio of 1.00:0.98 to suppress over-acylation; the crude coupling stream is used directly in a T3P®-mediated macrolactamisation at 50 °C in toluene, yielding a 16-membered ring system. This route delivers the same voxilaprevir API, with the intermediate providing the (2S,5S)-5-methylpyrrolidine-2-carboxylic acid motif as a critical conformational lock. Residual solvent analysis in the isolated intermediate must conform to USP <467> Class 3 limits (acetonitrile ≤ 410 ppm, ethyl acetate ≤ 5000 ppm); the final tablet formulation is tested for dissolution compliance per USP <711>, Apparatus II at 75 rpm.
When Scale-Up Shifts from Batch to Continuous Flow for Amide Bond Formation Under Acid Chloride ActivationIn kilo-lab settings exceeding 50 L, the batch-mode coupling between the P2–P3 acid and the macrocycle amine encounters heat-transport limitations that broaden the residence-time distribution and increase the epimerization risk. To address this, production campaigns at 100 kg scale have adopted a continuous-flow platform: the (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid is first converted to the corresponding acid chloride using 1.05 eq. of thionyl chloride in dichloromethane at 0 °C within a PFA tube reactor (ID 2.0 mm, residence time 45 s), then mixed with a pre-cooled stream of the amine hydrochloride and 2.5 eq. of triethylamine in a second microreactor chip maintained at –15 °C. Under these conditions, the US FDA guidance for continuous manufacturing (ICH Q13) is relevant, and the intermediate quality specification adds a requirement for N,N-dimethylformamide content below 20 ppm (derived from upstream solvent traces) because even 5 ppm residual DMF participates in Vilsmeier-type side reactions during SOCl₂ activation. The isolated crude wax is subjected to a solvent switch into methyl tert-butyl ether and crystallised by controlled cooling (0.2 °C/min) to yield the peptide intermediate in ≥98.5 area % purity. The final drug substance obtained from this intermediate—voxilaprevir—is formulated into fixed-dose combination tablets containing 100 mg voxilaprevir, 400 mg sofosbuvir, and 100 mg velpatasvir, with dissolution acceptance criteria per FDA dissolution database for ANDA filers.A single-point hydrate control failure in the vacuum drying tray dryer can cascade into a coupling yield collapse that remains undetectable by routine loss-on-drying checks. During the production of the title dipeptide acid, a short-term excursion above 60 % relative humidity in the milling suite introduces a monohydrate form that exhibits a broad endotherm centred at 72 °C (DSC) and a shift in the carbonyl stretching region from 1740 cm⁻¹ to 1715 cm⁻¹. When a batch containing 1.3 wt % moisture is deployed in the EDC/HOBt-mediated coupling, the in-situ generation of the O-acylisourea intermediate is competitively quenched; the active ester formation efficiency drops to 61 % of the baseline value, and the downstream macrolactamisation yield falls from 82 ± 2 % to 44 ± 5 %. Consequently, the incoming material specification for the intermediate mandates a Karl Fischer titre of ≤ 0.10 % w/w and a dedicated pre-drying protocol: the powder is held for 12 h at 40 °C under a vacuum of ≤ 10 mbar in a Guedu® agitated vacuum dryer with nitrogen breakthrough. The terminal voxilaprevir tablet batch must also pass ICH Q3D risk assessment for nickel, cobalt, and vanadium, with each element kept below its permitted daily exposure (e.g., Ni ≤ 60 μg/day) based on a maximum daily intake of one 100 mg dose.L-Proline-Derived Organocatalysis Bearing a (2S,5S)-5-Methyl Motif in Real-World Asymmetric Aldol ProcessesBeyond its role as an HCV protease inhibitor intermediate, (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid has found industrial utility as a pre-catalyst scaffold in enantioselective carbon–carbon bond formations, particularly for the production of chiral β-hydroxy ketones employed in statin side-chain synthesis. The compound is converted to its free secondary amine form via methyl ester saponification followed by hydrogenolysis, then used at 5 mol % loading in a 300 L jacketed glass-lined reactor to catalyse the aldol reaction between 4-fluorobenzaldehyde and acetone at –20 °C. The optimal catalytic activity requires the addition of 0.5 eq. of benzoic acid as a co-catalyst, which accelerates the formation of the enamine intermediate while suppressing the parasitic oxazolidinone cyclisation that otherwise consumes 8–12 % of the catalyst within 2 h. At full conversion, the (R)-aldol product is obtained in 94 % ee as determined by GC on a Chirasil-DEX CB column; the crude product is directly telescoped into a diastereoselective reduction to generate a key building block for rosuvastatin. From a compliance standpoint, the recovered catalyst stream must be monitored for trace heavy metals introduced by glass-lining wear – an internal specification of Fe ≤ 5 ppm and Ti ≤ 2 ppm is enforced to prevent contamination of the final API. The organocatalyst itself is typically supplied as a lyophilised powder with a chiral purity specification of ≥ 99.0 % ee, tested against ISO 9001:2015 batch release protocols.
|
Competitive (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Compound | Protecting Group Cleavage | C‑5 Configuration | Dominant Ring Pucker | HATU‑Mediated Coupling to H‑Leu‑NHMe | Epimerization Observed After Acid Deprotection |
|---|---|---|---|---|---|
| (2S,5S)-Moc‑Val‑5‑Me‑Pro‑OH | TFA 30 min; stable to H₂/Pd | cis‑methyl | Cγ‑exo (>85 % at 25 °C in D₂O) | 71 % isolated yield after single coupling | <0.3 % (²H‑NMR, 500 MHz) |
| (2S,5S)-Boc‑Val‑5‑Me‑Pro‑OH | TFA 15 min; cleaved by H₂/Pd* | cis‑methyl | Cγ‑exo | 78 % | <0.5 % |
| (2S,5R)-Moc‑Val‑5‑Me‑Pro‑OH | TFA 30 min; stable to H₂/Pd | trans‑methyl | Cβ‑exo (∼60 %) | 43 % | <0.3 % |
| (2S)-Moc‑Val‑Pro‑OH (no methyl) | TFA 30 min; stable to H₂/Pd | unsubstituted | γ‑turn mixture | 82 % | 1.1 % |